中国药房2024，Vol.35Issue(9)：1113-1117,5.DOI:10.6039/j.issn.1001-0408.2024.09.15
曲妥珠单抗生物仿制药对比原研药治疗复发或转移性HER-2阳性乳腺癌的药物经济学评价
Pharmacoeconomic evaluation of trastuzumab biosimilars versus original drug in the treatment of recurrent/metastatic HER-2 positive breast cancer
摘要
Abstract
OBJECTIVE To evaluate the cost-effectiveness of trastuzumab biosimilars(Hanquyou)versus original drug(Hesaiting)in the treatment of recurrent/metastatic human epidermal growth factor receptor-2(HER-2)positive breast cancer.METHODS A partitional survival model was constructed based on the NCT03084237 trial data.The simulation period was 3 weeks,and the simulation time was 10 years.Using costs and quality-adjusted life year(QALY)as the output indicator,the cost-utility analysis method was used to evaluate the cost-effectiveness of the two schemes mentioned above.Univariate and probabilistic sensitivity analyses were performed to verify the robustness of the basic analysis.RESULTS The costs of the trastuzumab biosimilars group and original drug group were 111 516.72 yuan and 111 122.30 yuan respectively,with health utility values of 1.52 QALYs and 1.36 QALYs,and ICER of 2 465.12 yuan/QALY,which were less than 3 times China's per capita gross domestic product(GDP)in 2023 as the threshold for willingness-to-pay(WTP)(268 200 yuan/QALY).Univariate sensitivity analysis showed that the cost of the trastuzumab biosimilars and original drug had a great impact on the ICER.The probabilistic sensitivity analysis showed that the probability of trastuzumab biosimilars being cost-effective was 100%at WTP threshold of 14 902 yuan/QALY.CONCLUSIONS When WTP threshold is 3 times China's GDP in 2023(268 200 yuan/QALY),compared with original drug,trastuzumab biosimilars have good cost-effectiveness in the treatment of recurrent/metastatic HER-2 positive breast cancer.关键词
曲妥珠单抗/人表皮生长因子受体2/乳腺癌/分区生存模型/药物经济学/成本-效用分析/原研药/生物仿制药Key words
trastuzumab/human epidermal growth factor receptor-2/breast cancer/partitional survival model/pharmacoeconomics/cost-utility analysis/original drug/biosimilars分类
医药卫生引用本文复制引用
邢玥,刘通,滕雪,董梅..曲妥珠单抗生物仿制药对比原研药治疗复发或转移性HER-2阳性乳腺癌的药物经济学评价[J].中国药房,2024,35(9):1113-1117,5.基金项目
黑龙江省卫生健康委科研课题(No.20221313010972) （No.20221313010972）
